• VOD-new-1
  • linkedin
Tuesday, 05 November 2013 12:44

Technical Report: Comparison of Dissolution Properties of Piroxicam Using Microcrystalline Cellulose and a New Excipient (LoxOral™)

The purpose of this study was to evaluate the potential of LoxOral to enhance the dissolution properties of piroxicam and to evaluate its utility in comparison to MCC delivery systems.

Introduction:

illus-loxoral

During the last decade, the trend in drug discovery has increased the number of active pharmaceutical ingredients (APIs) that exhibit high lipophilicity and poor water solubility, also associated with poor dissolution characteristics (Vogt et al., 2008). Dissolution rate in the gastrointestinal tract is the rate limiting factor for the absorption of many of these drugs, which therefore suffer from poor oral bioavailability (Zimmermann et al., 2009).

In order to enhance the dissolution of poorly water-soluble drugs, an increasing number of pharmaceutical formulation technologies are being developed to address this challenge of drug product development (Uchiyama et al., 2010). Many pharmaceutical studies have focused their attention on the production of multifunctional excipients, once the choice of excipients becomes critical in terms of delivery system functionality and quality. Excipients with multiple functional properties confer many advantages such as manufacturing efficiency and reduced production costs (Builders et al., 2010).

Microcrystalline cellulose (MCC) is a purified, partially depolymerized cellulose prepared by treating alpha cellulose, obtained as a pulp from fibrous plant material with mineral acids (Gohel et al., 2007). It is widely used as filler, disintegrant and binder of oral tablets, pellets and capsules (Nikolakakis et al., 2006). MCC is considered one of the most useful fillers due to its excellent compatibility at low pressures, high dilution potential, chemical inertness and compatibility with most drugs (Kalita et al., 2013). However, according to Chamsai & Sriamornsak (2013), most drugs prepared with MCC show a tendency toward prolonged release due to a lack of disintegration.

LoxOral, manufactured by PCCA, is an innovative excipient for use in capsule formulations. It improves dissolution of all types of APIs, including drugs with poor water solubility. It is gluten- and casein-free, Sodium Lauryl Sulfate (SLS)-free, lactose-free, soy-free, dye-free and magnesium stearate-free. It also contains an ingredient (isomalt) which has shown potential prebiotic effects (Gibson et al., 2010). LoxOral is an all-in-one base with improved dissolution, excellent flowability and reduced static. It is minimally hygroscopic, resisting moisture absorption and providing optimal stability.

Piroxicam is a member of the oxicam group of nonsteroidal anti-inflammatory drugs (NSAIDs), and is indicated for treatment of acute or chronic signs and symptoms of osteoarthritis and rheumatoid arthritis (Karatas et al., 2005). According to the Biopharmaceutic Drug Classification System (BCS) proposed by Amidon et al. (1995), piroxicam is a class II drug, characterized by low solubility–high permeability. Over the years, several techniques have been used to improve the oral bioavailability of piroxicam by accelerating its dissolution rate in biological fluids at physiological pH (Yuksel et al., 2003).

Abstract:

Ketoconazole is an imidazole antifungal drug that can be administered orally and is characterized by low solubility, high permeability (class II by BCS). The capability of a new excipient, LoxOral, manufactured by PCCA, to enhance the dissolution of drugs with poor water solubility was investigated by USP dissolution testing and compared to microcrystalline cellulose (MCC). The capsules containing ketoconazole in LoxOral produced a higher in vitro dissolution when compared to corresponding mixture with MCC. It was also the only combination which complied with the USP dissolution specification for the drug (80.78% at 30 min). The results suggest that LoxOral, is a useful and powerful excipient tool to accelerate dissolution and potentially improve the oral bioavailability of drugs with poor water solubility.

Conclusions:

LoxOral was shown to be a successful excipient to improve the dissolution rate of piroxicam. The increase in the rate would potentially provide the rapid bioavailability and onset of action after the drug is taken orally. LoxOral-based formulations have proven to be a most promising delivery system for oral bioavailability enhancement of BCS Class II drugs such as piroxicam.

Download the complete PDF detailing the results of this study.

Click to learn more about LoxOral.